Reem W Alreshidi¹, Malik Almalki¹*, Shaker Alreshidi² and Mohammad Almalki³

¹Department of Pediatrics, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
²King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia
³King Saud Medical City, Riyadh, Saudi Arabia

*Corresponding Author: Malik Almalki, Department of Pediatrics, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

Received: July 05, 2022; Published: September 28, 2022

Abstract

Purpose: The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infected millions of people of all ages worldwide to date. The majority of confirmed cases were among adults and approximately 2% of the confirmed cases are for children. Covid-19 vaccine had high safety and efficacy. Nevertheless, adverse reaction has been reported, approximately 90% of all vaccine recipients reported local and at least one systemic reaction. In this case report, we report a case of anaphylactic reaction in a child after dose of Pfizer-BioNTech COVID-19 vaccine. Up to our knowledge, this is the first case to be reported of anaphylactic reaction in a child after dose of Pfizer-BioNTech COVID-19 vaccine

Observations: A 13 year old boy, presented to our paediatric emergency department (PED) with anaphylactic reaction, complaint of rash and shortness of breath (SOB) 13 minutes after received first dose Pfizer-BioNTech COVID-19 vaccine. management involved systemic epinephrine, antihistamine and steroid.

Conclusions and Importance: Due to the recent authorization of COVID-19 vaccine in children of 12 years or older, children with anaphylaxis post- vaccination are expected. In addition to the necessary observation at vaccine centre, necessary supplies to immediately manage anaphylaxis, should be available in vaccination centres.

Keywords: COVID-19; Vaccine; Allergy; Anaphylaxis; Paediatric; Adverse Effect

References

1. WHO Records COVID-19.
2. Shekerdemian LS., et al. “Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units”. JAMA Pediatric 174 (2020): 868-873.
3. Dong Y., et al. “Epidemiology of COVID-19 among children in China”. Pediatrics 145 (2020): e20200702.
4. Liguoro I., et al. “SARS-COV-2 infection in children and newborns: a systematic review”. European Journal of Pediatrics 179 (2020): 1029-1046.
5. YM Kazzaz., et al. “Hospital preparedness and management of pediatric population during COVID-19 outbreak”. Annals of Thoracic Medicine 15 (2020): 107-117.
6. Ministry of MOH Records COVID-19.
7. Frenck RW., et al. “C4591001 Clinical Trial Group. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents”. The New England Journal of Medicine 3 (2021): 239-250.
8. Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Pfizer-BioNTech COVID-19 Vaccine, CDC (2021).
9. Shimabukuro T and Nair N. “Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine”. JAMA 8 (2021): 780-781.
10. Rüggeberg JU., et al. “Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data”. Vaccine31 (2007): 5675-5684.
11. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021”. Morbidity and Mortality Weekly Report 70 (2020): 125-129.
12. Polack FP., et al. “C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine”. The New England Journal of Medicine 27 (2020): 2603-2615.
13. Rüggeberg JU., et al. Brighton Collaboration Anaphylaxis Working Group. “Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data”. Vaccine 25 (2007): 5675-5684.
14.  

Citation

Citation: Malik Almalki., et al. “Anaphylactic Reaction in a Child After Dose of Pfizer-BioNTech COVID-19 Vaccine". Acta Scientific Paediatrics 5.10 (2022): 13-15.

Copyright

Copyright: © 2022 Malik Almalki., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.